When Valproic Acid Does Not Control Seizures in Lennox-Gastaut Syndrome

Valproic acid (VPA) is a cornerstone of treatment for Lennox-Gastaut syndrome. When VPA alone fails to achieve adequate seizure control, a specific, evidence-based adjunctive step is indicated.

This protocol defines the first adjunctive agent to add — and specifies a required dosing approach driven by a clinically significant pharmacokinetic interaction between VPA and the added medication.

The recommended first adjunct must be started at a reduced dose with a slow titration schedule, owing to the way VPA alters its metabolism. The complete regimen, titration guidance, and clinical thresholds are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1002/epi4.13075

If VPA therapy does not provide adequate seizure control, LTG should be added as the first adjunctive therapy.

Since VPA inhibits LTG metabolism, a decreased LTG dose with slow titration should be used.

View source ↗